{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T02:27:56Z","timestamp":1788834476278,"version":"build-2803163510"},"reference-count":30,"publisher":"Walter de Gruyter GmbH","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Low skeletal muscle mass has been increasingly recognized as a negative prognostic factor in oncology. According to the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), sarcopenia is defined as a progressive and generalized skeletal muscle disorder characterized by the loss of muscle strength and muscle mass, which can lead to impaired physical performance. This study aimed to investigate whether baseline low muscle mass and dynamic changes in muscle mass during immunotherapy could predict treatment response and survival in patients with metastatic renal cell carcinoma (mRCC) treated with Nivolumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>This retrospective cohort study included 50 mRCC patients (35 men, 15 women; mean age 59.1 \u00b1 10.2 years) who received Nivolumab between 2019 and 2022 and underwent abdominal computed tomography (CT) before and during treatment. Muscle mass was assessed by calculating the skeletal muscle index (SMI) at the third lumbar vertebra using standard Hounsfield unit thresholds (-29 to +150 HU). Treatment response was evaluated according to immune Response Evaluation Criteria in Solid Tumors (iRECIST). Overall survival (OS) and progression-free survival (PFS) were analyzed using Kaplan\u2013Meier curves and Cox regression models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Low muscle mass was identified in 60% of patients and was significantly associated with multiple organ metastases (p = 0.003). Patients with baseline low muscle mass or a negative change in SMI during treatment demonstrated poorer treatment response (p = 0.027 and p = 0.021, respectively). Both OS and PFS were significantly shorter in patients with low muscle mass and those with declining muscle mass during treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Pre-treatment low muscle mass and muscle mass decline during immunotherapy were independently associated with inferior survival and treatment response in mRCC patients receiving Nivolumab. CT-based muscle mass assessment may serve as an imaging-based prognostic biomarker in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2478\/raon-2025-0065","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T16:58:39Z","timestamp":1765904319000},"page":"624-634","source":"Crossref","is-referenced-by-count":2,"title":["Baseline and dynamic changes in skeletal muscle mass as predictive biomarkers in patients with metastatic renal cell carcinoma treated with Nivolumab"],"prefix":"10.2478","volume":"59","author":[{"given":"Erdem","family":"Ozkan","sequence":"first","affiliation":[{"name":"Radiology Department, Kastamonu Training and Research Hospital , Kastamonu , T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murathan","family":"Koksal","sequence":"additional","affiliation":[{"name":"Radiology Department, Ankara Bilkent City Hospital , Ankara , T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bunyamin","family":"Ece","sequence":"additional","affiliation":[{"name":"Radiology Department, Kastamonu University, Faculty of Medicine , Kastamonu , T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Koyun","sequence":"additional","affiliation":[{"name":"Radiology Department, Kastamonu Training and Research Hospital , Kastamonu , T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer Faruk","family":"Kuzu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, \u00c7ank\u0131r\u0131 State Hospital , \u00c7ank\u0131r\u0131 , T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuf","family":"Acikgoz","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Lokman Hekim University Ankara Hospital , Ankara , T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efnan","family":"Algin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ankara Bilkent City Hospital , Ankara , T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2025,12,16]]},"reference":[{"key":"2026071215565119818_j_raon-2025-0065_ref_001","doi-asserted-by":"crossref","unstructured":"Capitanio U, Bensalah K, Bex A, Boorjian SA, Bray F, Coleman J, et al. Epidemiology of renal cell carcinoma. Eur Urol 2019; 75: 74-8. doi: 10.1016\/j.eururo.2018.08.036","DOI":"10.1016\/j.eururo.2018.08.036"},{"key":"2026071215565119818_j_raon-2025-0065_ref_002","unstructured":"Ferlay J, Ervik M, Lam, F, Colombet M, Mery L, Pi\u00f1eros M, et al. Global cancer observatory: cancer today. Lyon, France: International Agency for Research on Cancer; 2020."},{"key":"2026071215565119818_j_raon-2025-0065_ref_003","doi-asserted-by":"crossref","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024; 74: 229-63. doi: 10.3322\/caac.21834","DOI":"10.3322\/caac.21834"},{"key":"2026071215565119818_j_raon-2025-0065_ref_004","doi-asserted-by":"crossref","unstructured":"Mathers CD. History of global burden of disease assessment at the World Health Organization. Arch Public Health 2020: 24; 78-87. doi: 10.1186\/s13690-020-00458-3","DOI":"10.1186\/s13690-020-00458-3"},{"key":"2026071215565119818_j_raon-2025-0065_ref_005","doi-asserted-by":"crossref","unstructured":"Sherafat NS, Keshavarz A, Mardi A, Mohammadiara A, Aghaei M, Aghebati-Maleki L, et al. Rationale of using immune checkpoint inhibitors (ICIs) and anti-angiogenic agents in cancer treatment from a molecular perspective. Clin Exp Med 2025; 25: 238. doi: 10.1007\/s10238-025-01751-7","DOI":"10.1007\/s10238-025-01751-7"},{"key":"2026071215565119818_j_raon-2025-0065_ref_006","doi-asserted-by":"crossref","unstructured":"Venur VA, Joshi M, Nepple KG, Zakharia Y. Spotlight on nivolumab in the treatment of renal cell carcinoma: design, development, and place in therapy. Drug Des Devel Ther 2017: 11: 1175-82. doi: 10.2147\/DDDT.S110209","DOI":"10.2147\/DDDT.S110209"},{"key":"2026071215565119818_j_raon-2025-0065_ref_007","doi-asserted-by":"crossref","unstructured":"Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruy\u00e8re O, Cederholm T, et al. Writing group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 2019; 48: 16-31. doi: 10.1093\/ageing\/afy169","DOI":"10.1093\/ageing\/afy169"},{"key":"2026071215565119818_j_raon-2025-0065_ref_008","doi-asserted-by":"crossref","unstructured":"Psutka SP, Boorjian SA, Moynagh MR, Schmit GD, Costello BA, Thompson RH, et al. Decreased skeletal muscle mass is associated with an increased risk of mortality after radical nephrectomy for localized renal cell cancer. J Urol 2016; 195: 270-6. doi: 10.1016\/j.juro.2015.08.072","DOI":"10.1016\/j.juro.2015.08.072"},{"key":"2026071215565119818_j_raon-2025-0065_ref_009","doi-asserted-by":"crossref","unstructured":"Sharma P, Zargar-Shoshtari K, Caracciolo JT, Fishman M, Poch MA, Pow-Sang J, et al. Sarcopenia as a predictor of overall survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. Urol Oncol 2015; 33: 339. e17-23. doi: 10.1016\/j.urolonc.2015.01.011","DOI":"10.1016\/j.urolonc.2015.01.011"},{"key":"2026071215565119818_j_raon-2025-0065_ref_010","doi-asserted-by":"crossref","unstructured":"Fukushima H, Nakanishi Y, Kataoka M, Tobisu K, Koga F. Prognostic significance of sarcopenia in patients with metastatic renal cell carcinoma. J Urol 2016; 195: 26-32. doi: 10.1016\/j.juro.2015.08.071","DOI":"10.1016\/j.juro.2015.08.071"},{"key":"2026071215565119818_j_raon-2025-0065_ref_011","doi-asserted-by":"crossref","unstructured":"Nikodinovska V, Ivanoski S. Sarcopenia, more than just muscle atrophy: imaging methods for the assessment of muscle quantity and quality. Rofo 2023; 195: 777-89. doi: 10.1055\/a-2057-0205.","DOI":"10.1055\/a-2057-0205"},{"key":"2026071215565119818_j_raon-2025-0065_ref_012","doi-asserted-by":"crossref","unstructured":"Ryan AM, Prado CM, Sullivan ES, Power DG, Daly LE. Effects of weight loss and sarcopenia on response to chemotherapy, quality of life, and survival. Nutrition 2019; 67-68: 110539. doi: 10.1016\/j.nut.2019.06.020","DOI":"10.1016\/j.nut.2019.06.020"},{"key":"2026071215565119818_j_raon-2025-0065_ref_013","doi-asserted-by":"crossref","unstructured":"Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, et al. RECIST working group. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 2017; 18: e143-52. doi: 10.1016\/S1470-2045(17)30074","DOI":"10.1016\/S1470-2045(17)30074-8"},{"key":"2026071215565119818_j_raon-2025-0065_ref_014","doi-asserted-by":"crossref","unstructured":"Aubrey J, Esfandiari N, Baracos VE, Buteau FA, Frenette J, Putman CT, et al. Measurement of skeletal muscle radiation attenuation and basis of its biological variation. Acta Physiol 2014; 210: 489-97. doi: 10.1111\/apha.12224","DOI":"10.1111\/apha.12224"},{"key":"2026071215565119818_j_raon-2025-0065_ref_015","doi-asserted-by":"crossref","unstructured":"Ryan AM, Power DG, Daly L, Cushen SJ, N\u00ed Bhuachalla \u0112, Prado CM. Cancer-associated malnutrition, cachexia and sarcopenia: the skeleton in the hospital closet 40 years later. Proc Nutr Soc 2016; 75: 199-211. doi: 10.1017\/S002966511500419X","DOI":"10.1017\/S002966511500419X"},{"key":"2026071215565119818_j_raon-2025-0065_ref_016","doi-asserted-by":"crossref","unstructured":"Mourtzakis M, Prado CM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab 2008; 33: 997-1006. doi: 10.1139\/H08-075","DOI":"10.1139\/H08-075"},{"key":"2026071215565119818_j_raon-2025-0065_ref_017","doi-asserted-by":"crossref","unstructured":"Lee J, Suh J, Song C, You D, Jeong IG, Hong B; et al. Association between sarcopenia and survival of patients with organ-confined renal cell carcinoma after radical nephrectomy. Ann Surg Oncol 2022; 29: 2473-9. doi: 10.1245\/s10434-021-10881-7","DOI":"10.1245\/s10434-021-10881-7"},{"key":"2026071215565119818_j_raon-2025-0065_ref_018","doi-asserted-by":"crossref","unstructured":"Prado CM, Birdsell LA, Baracos VE. The emerging role of computerized tomography in assessing cancer cachexia. Curr Opin Support Palliat Care 2009; 3: 269-75. doi: 10.1097\/SPC.0b013e328331124a.","DOI":"10.1097\/SPC.0b013e328331124a"},{"key":"2026071215565119818_j_raon-2025-0065_ref_019","doi-asserted-by":"crossref","unstructured":"Hu X, Liao DW, Yang ZQ, Yang WX, Xiong SC, Li X. Sarcopenia predicts prognosis of patients with renal cell carcinoma: a systematic review and meta-analysis. Int J Brauz Urol 2020; 46: 705-15. doi. 10.1590\/S1677-5538. IBJU.2019.0636","DOI":"10.1590\/s1677-5538.ibju.2019.0636"},{"key":"2026071215565119818_j_raon-2025-0065_ref_020","doi-asserted-by":"crossref","unstructured":"Herrmann T, Mione C, Montoriol PF, Molnar I, Ginzac A, Durando X, et al. Body mass index, sarcopenia, and their variations in predicting outcomes for patients treated with nivolumab for metastatic renal cell carcinoma. Oncology 2022; 100: 114-23. doi: 10.1159\/000520833","DOI":"10.1159\/000520833"},{"key":"2026071215565119818_j_raon-2025-0065_ref_021","doi-asserted-by":"crossref","unstructured":"Sharma P, Zargar-Shoshtari K, Caracciolo JT, Fishman M, Poch MA, Pow-Sang J, et al. Sarcopenia as a predictor of overall survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. Urol Oncol 2015; 33: 339. e17-23. doi: 10.1016\/j.urolonc.2015.01.011","DOI":"10.1016\/j.urolonc.2015.01.011"},{"key":"2026071215565119818_j_raon-2025-0065_ref_022","doi-asserted-by":"crossref","unstructured":"Ueki H, Hara T, Okamura Y, Bando Y, Terakawa T, Furukawa J, et al. Association between sarcopenia based on psoas muscle index and the response to nivolumab in metastatic renal cell carcinoma: a retrospective study. Investig Clin Urol 2022; 63: 415-24. doi: 10.4111\/icu.20220028","DOI":"10.4111\/icu.20220028"},{"key":"2026071215565119818_j_raon-2025-0065_ref_023","doi-asserted-by":"crossref","unstructured":"Ishihara H, Takagi T, Kondo T, Fukuda H, Yoshida K, Iizuka J et al. Effect of changes in skeletal muscle mass on oncological outcomes during first-line sunitinib therapy for metastatic renal cell carcinoma. Target Oncol 2018; 13: 745-55. doi: 10.1007\/s11523-018-0600-3","DOI":"10.1007\/s11523-018-0600-3"},{"key":"2026071215565119818_j_raon-2025-0065_ref_024","doi-asserted-by":"crossref","unstructured":"Severinsen MCK, Pedersen BK. Muscle-organ crosstalk: the emerging roles of myokines. Endocr Rev 2020; 41: 594-609. doi: 10.1210\/endrev\/bnaa016","DOI":"10.1210\/endrev\/bnaa016"},{"key":"2026071215565119818_j_raon-2025-0065_ref_025","doi-asserted-by":"crossref","unstructured":"Deng Y, Zhao L, Huang X, Zeng Y, Xiong Z, Zuo M. Contribution of skeletal muscle to cancer immunotherapy: a focus on muscle function, inflammation, and microbiota. Nutrition 2023; 105: 111829. doi: 10.1016\/j. nut.2022.111829","DOI":"10.1016\/j.nut.2022.111829"},{"key":"2026071215565119818_j_raon-2025-0065_ref_026","doi-asserted-by":"crossref","unstructured":"Li S, Wang T, Tong G, Li X, You D, Cong M. Prognostic impact of sarcopenia on clinical outcomes in malignancies treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Front Oncol 2021; 11: 726257. doi: 10.3389\/fonc.2021.726257","DOI":"10.3389\/fonc.2021.726257"},{"key":"2026071215565119818_j_raon-2025-0065_ref_027","doi-asserted-by":"crossref","unstructured":"Bilen MA, Martini DJ, Liu Y, Shabto JM, Brown JT, Williams M, et al. Combined effect of sarcopenia and systemic inflammation on survival in patients with advanced stage cancer treated with immunotherapy. Oncologist 2020; 25: e528-35. doi: 10.1634\/theoncologist.2019-0751","DOI":"10.1634\/theoncologist.2019-0751"},{"key":"2026071215565119818_j_raon-2025-0065_ref_028","doi-asserted-by":"crossref","unstructured":"McKinnon MB, Rini BI, Haake SM. Biomarker-informed care for patients with renal cell carcinoma. Nat Cancer 2025; 6: 573-83. doi: 10.1038\/s43018-025-00942-1","DOI":"10.1038\/s43018-025-00942-1"},{"key":"2026071215565119818_j_raon-2025-0065_ref_029","doi-asserted-by":"crossref","unstructured":"Sahin TK, Guven DC. Prognostic impact of myosteatosis on survival with immune checkpoint inhibitors: a systematic review and meta-analysis. Clin Nutr ESPEN 2024; 63: 829-36. doi: 10.1016\/j.clnesp.2024.08.015","DOI":"10.1016\/j.clnesp.2024.08.015"},{"key":"2026071215565119818_j_raon-2025-0065_ref_030","doi-asserted-by":"crossref","unstructured":"Ahn H, Kim DW, Ko Y, Ha J, Shin YB, Lee J, et al. Updated systematic review and meta-analysis on diagnostic issues and the prognostic impact of myosteatosis: a new paradigm beyond sarcopenia. Ageing Res Rev 2021; 70: 101398. doi: 10.1016\/j.arr.2021.101398","DOI":"10.1016\/j.arr.2021.101398"}],"container-title":["Radiology and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/raon-2025-0065","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T01:03:06Z","timestamp":1783904586000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/raon-2025-0065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":30,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,12,16]]},"published-print":{"date-parts":[[2025,12,1]]}},"alternative-id":["10.2478\/raon-2025-0065"],"URL":"https:\/\/doi.org\/10.2478\/raon-2025-0065","relation":{},"ISSN":["1581-3207"],"issn-type":[{"value":"1581-3207","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,1]]}}}